A practical reference on LC-MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-28. Anything still debated is marked as such rather than presented as settled.
Analytical identification of NMN commonly uses high-performance liquid chromatography with ultraviolet detection, liquid chromatography-mass spectrometry, and nuclear magnetic resonance spectroscopy; HPLC can estimate purity by peak area, while mass spectrometry confirms molecular mass and fragmentation. NMR provides structural confirmation. Because NMN is charged, ion-pairing reagents or hydrophilic interaction liquid chromatography columns can improve retention and peak shape. In biological samples, LC-MS/MS with stable isotope internal standards is often used to quantify NMN and related NAD+ metabolites. Method validation is important because matrix effects and rapid enzymatic interconversion can complicate measurements.
Quality control for NMN typically checks identity, assay purity, residual solvents, heavy metals, and microbial limits, depending on the intended use and market. A certificate of analysis may report appearance, solubility, water content, and storage recommendations. Independent verification can compare chromatographic retention time and mass spectrum against a certified reference standard. Regulatory expectations differ between research chemicals, dietary ingredients, and pharmaceutical products. Impurity profiles and stability data are often requested for product approval, and open questions remain about how best to standardize NMN measurements across laboratories.
NMN is present in small amounts in some foods, including certain vegetables, fruits, and animal products, but food content varies widely and is not well standardized. In laboratory research, NMN is used as a tool compound to study NAD+ metabolism, mitochondrial function, and cellular stress responses. Animal studies have reported changes in NAD+ levels and various physiological measures after NMN administration, but species differences and study designs limit direct extrapolation to humans. Human trials have largely focused on safety, tolerability, and pharmacokinetics, with fewer studies examining clinical endpoints.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide ring attached to a ribose sugar that carries a phosphate group. The molecular formula is C11H15N2O8P, and the molar mass is about 334.22 grams per mole. In cells, NMN is an intermediate in the salvage pathway that recycles nicotinamide to maintain NAD+ levels. It is not the same compound as NAD+, although it is a direct precursor in one enzymatic step.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for solid free acid or salt forms |
| Solubility | Freely soluble in water | Polar nucleotide; limited solubility in nonpolar solvents |
| Typical storage | -20 °C or below | Desiccated, protected from light |
| Common analytical method | LC-MS or HPLC-UV | Used for identity and purity assessment |
| Common synonyms | Nicotinamide ribonucleotide; beta-NMN | NMN is the usual abbreviation |
Quality control for NMN materials typically includes identity, assay, impurity, and residual solvent tests. Certificates of analysis may report HPLC purity, water content, heavy metals, and microbial limits depending on the intended use. Because commercial NMN is sold as a research chemical or ingredient rather than a standardized drug in many jurisdictions, specifications can vary between suppliers. Independent verification can involve comparing retention time, mass spectrum, and NMR data against a reference standard. Open questions remain about how best to standardize purity claims and biological potency across different production methods.
Analytical identification of NMN usually combines chromatographic separation with mass spectrometric detection. High-performance liquid chromatography coupled to tandem mass spectrometry is common for quantifying NMN in biological matrices and finished materials. Because NMN and related nucleotides share similar masses and retention behavior, method development must resolve potential interferences such as nicotinamide riboside and NAD+. Ultraviolet detection at approximately 260 nm can be used for purity checks when concentrations are sufficient. Nuclear magnetic resonance spectroscopy provides structural confirmation and can distinguish anomeric forms.
Dietary sources of NMN include small amounts in certain vegetables, fruits, and other foods, although exact values vary by sample and method. Endogenous NMN concentrations are tightly regulated and often low, making measurement in blood or tissues technically demanding. After oral intake, NMN is thought to be rapidly metabolized in the intestine and liver, and intact NMN may not reach all tissues at high levels. Some rodent studies report increases in tissue NAD+ after oral NMN, while human data remain limited and sometimes rely on blood NAD+ metabolites rather than direct tissue measures.
Research on NMN has focused on aging, metabolic regulation, exercise capacity, and insulin sensitivity, but findings are preliminary. Many human trials are small, short in duration, and use different endpoints, which complicates comparison across studies. No national regulator has approved NMN as a therapeutic drug for any indication. In some countries it is sold as a supplement or research chemical, while other jurisdictions have questioned its status under food or supplement laws. Claims about extending human lifespan or reversing aging are not supported by established clinical evidence.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms, including bacteria, plants, and mammals. Its structure consists of a nicotinamide ring attached to a ribose-phosphate group. NMN functions as an intermediate in the NAD+ salvage pathway, a recycling route that regenerates nicotinamide adenine dinucleotide. The enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+.
Quality control for NMN focuses on identity, purity, and the absence of harmful contaminants. Certificates of analysis may report high-performance liquid chromatography purity, mass spectrometry identity, residual solvents, heavy metals, and microbial limits, depending on grade and intended use. Because NMN can exist as different isomers, salts, or hydrates, specification sheets should state the exact form being tested. There is no single globally harmonized purity standard for NMN products. Open questions include which degradation products are most relevant under real-world storage and how analytical results from different laboratories can be compared reliably.
Analytical measurement of NMN typically uses reversed-phase high-performance liquid chromatography with ultraviolet detection near 260 nm. Mass spectrometry, often coupled to liquid chromatography, provides sensitive quantification and confirmatory identification in biological matrices. Nuclear magnetic resonance spectroscopy is used to verify molecular structure and distinguish related nucleotides. Because NMN is polar and poorly retained on conventional reversed-phase columns, ion-pairing reagents or hydrophilic interaction chromatography are sometimes employed. Reported purity values depend on the chosen method, calibration standard, and whether related substances are resolved.
A centenarian is a person who has reached the age of 100. Because life expectancies at birth worldwide are well below 100, the term is invariably associated with longevity. The United Nations estimated that there were 316,600 living centenarians worldwide in 2012, and 573,000 in 2020, almost quadruple the 2000 estimate of 151,000. As world population and life expectancy continue to increase, the number of centenarians is expected to increase substantially in the 21st century. According to the Office of National Statistics in the United Kingdom, one-third of babies born in the country in 2013 are expected to live to 100. According to a 1998 United Nations demographic survey, Japan is expected to have 272,000 centenarians by 2050; other sources suggest that the number could be closer to 1 million. The incidence of centenarians in Japan was one per 3,522 people in 2008. In Japan (as in most countries), the population of centenarians is highly skewed towards women. Japan in fiscal year 2016 had 57,525 female centenarians, while there were 8,167 males, a ratio of 7:1. The increase of centenarians was even more skewed, at 11.6:1.
Xanthoria parietina hosts a diverse array of lichenicolous fungi—fungi that live on lichens. As of 2017, at least 41 species of lichenicolous fungi have been reported on X. parietina, including both obligate parasites and facultative colonizers. Examples include Athelia arachnoidea, Catillaria nigroclavata, and Capronia suijae. While some of these fungi may be pathogenic, others colonize the lichen without causing obvious damage to the thallus. In some cases, multiple lichenicolous and saprotrophic fungi can form complex communities on decaying thalli of X. parietina. One study in Austria documented ten different fungal species simultaneously colonizing damaged lichen thalli. The most visually apparent was Xanthoriicola physciae, while the dematiaceous hyphomycete Cladosporium macrocarpum was the most abundant colonizer, covering large areas of the thallus and apothecia with dark cottony filaments. This fungus causes visible discoloration and unevenness of the apothecial discs before eventually destroying the lichen structure. Other notable parasites included Lichenoconium xanthoriae, Lichenodiplis poeltii, and Pyrenochaeta xanthoriae. The highly destructive Marchandiomyces aurantiacus forms distinctive pale orange crumbles on the lichen surface, ultimately shrinking the thallus to a bleached, fragile film that clings to the substrate before complete decay.
==== Vascular tissue ==== High rates of cardiovascular disease creates a high demand for grafts for vascular bypass surgery, especially small-diameter grafts which prevent occlusion. Modifying vascular tissue grafts with RGD has been shown to inhibit platelet adhesion, improve cell infiltration and enhance endothelialization. There have also been efforts to regenerate damaged heart tissues by applying cardiac patches following myocardial infarction. The addition of RGD onto a cardiac tissue scaffold has been shown to promote cell adhesion, prevent apoptosis and enhance tissue regeneration. RGD peptide has also been used to improve endothelial cell adhesion and proliferation on synthetic heart valves.
== Political composition == It was possible for the ILEA to have a majority of Labour members when the GLC had a majority of Conservative members, and this happened from 1970 to 1973 and 1977 to 1981. In addition, most of the important decisions taken by the ILEA were taken by its Education Committee, on which every member sat. The Education Committee could also co-opt members with experience of education, some of them representing the teaching unions. The initial composition of the ILEA in 1964 was 43 Labour members to 9 Conservatives, with one Independent. After the 1967 election the Conservatives won a majority, and Christopher Chataway became Leader. However, Labour won control in 1970 and Ashley Bramall began his long leadership. His term saw the ILEA go over to comprehensive education, and the abolition of school corporal punishment. He retained power despite the Conservative election victory in the 1977 GLC elections. When the Left, under Ken Livingstone, won control of the GLC after the 1981 elections, Bramall lost his position in an internal Labour Party vote, being replaced by Bryn Davies. Livingstone later expressed regret for this decision and expressed his admiration for Bramall's leadership abilities. The remaining years of the ILEA saw a succession of left-wing leaderships, none of which lasted long or established a strong reputation. Frances Morrell, formerly an assistant to Tony Benn, led a feminist ILEA from 1983 to 1987 which threatened to defy its rate-capping in November 1984, before Neil Fletcher took over.
General standards for broadcasting are found in the Audiovisual Media Services Directive 2010. It defines an audiovisual media services to mean those 'devoted to providing programmes, under the editorial responsibility of a media service provider, to the general public, in order to inform, entertain or educate, to the general public by electronic communications networks', either on TV or an 'on-demand' service. An 'on-demand' service involves 'viewing of programmes at the moment chosen by the user and at his individual request on the basis of a catalogue of programmes selected by the media service provider'. Member states must ensure audiovisual services 'do not contain any incitement to hatred' based on race, sex, religion, nationality or other protected characteristics. Article 9 prohibits media with 'surreptitious' communication or 'subliminal' techniques, to 'prejudice respect for human dignity', that would 'promote any discrimination', prejudice health and safety or 'encourage behaviour grossly prejudicial to the protection of the environment'. Social media on Facebook, YouTube or Twitter may be thought to be exempt as they lack 'editorial responsibility', however each use algorithms to exert 'effective control' and profit from arrangement of media.
Sources: en.wikipedia.org
==== Dehydration ==== To combat dehydration, sufficient fresh drinking water should be provided. Here, too, you can try to increase the cat's voluntary water intake by adding meat broth or tuna juice. Switching to wet food also often leads to increased fluid intake. Dehydrated cats or animals with volume deficiency require fluid administration with correction of electrolytes. Renal azotemia cannot be influenced in this way. The administration of sterile infusion solutions under the skin by the owner must be viewed critically. These also ultimately enter the vascular system and conventional infusion solutions inevitably lead to a permanent excess of sodium. This form of treatment should therefore only be carried out if the condition and hydration status improve and there are no disturbances in blood pressure or potassium levels. Infusion solutions for cats in stage IV should contain a maximum of 40 mmol/L sodium and about 13 mmol/L (max. 30 mmol/L) potassium (half-electrolyte solution with potassium substitution).
SR-16435 is a drug which acts as a potent partial agonist at both the μ-opioid receptor and nociceptin receptor. In animal studies it was found to be a potent analgesic, with results suggestive of reduced development of tolerance and increased activity against neuropathic pain compared to classic μ-selective agonists.
== References == Charpin, Dominique (2010). Writing, Law, and Kingship in Old Babylonian Mesopotamia. University of Chicago Press. ISBN 978-0-226-10159-0. Charpin, Dominique (2023). "Old Babylonian Law and Justice according to Letters and Legal Documents". In Démare-Lafont, Sophie; Fleming, Daniel E. (eds.). Judicial Decisions in the Ancient Near East. SBL Press. pp. 103–222. doi:10.2307/jj.8784672. ISBN 978-1-62837-486-5. Harris, Rivkah (1969). "Notes on the Babylonian Cloister and Hearth: A Review Article". Orientalia. 38 (1): 133–145. ISSN 0030-5367. JSTOR 43079057. Harris, Rivkah (1976). "On Kinship and Inheritance in Old Babylonian Sippar". Iraq. 38 (2): 129–132. doi:10.2307/4200036. ISSN 0021-0889. Jacquet, Antoine (2013). "Family Archives in Mesopotamia during the Old Babylonian Period". In Faraguna, Michele (ed.). Archives and archival documents in ancient societies: Legal Documents in Ancient Societies IV: Trieste 30 September-1 October 2011. Edizioni Università di Trieste. pp. 63–85. ISBN 978-88-8303-460-2. De Graef, Katrien (2016). "Cherchez la femme! The Economic Role of Women in Old Babylonian Sippar". In Lion, Brigitte; Michel, Cécile (eds.). The Role of Women in Work and Society in the Ancient Near East. De Gruyter. pp. 270–295. doi:10.1515/9781614519089-016. ISBN 978-1-61451-908-9.
There is debate as to whether the Kingdom of Poland, as a state, was formally replaced by the Vistula Land. Towns were stripped of their charters in reprisal and turned into villages. The Russian Partition of Poland was made an official province of the Russian Empire in 1867. In the early 20th century, a major part of the Russian Revolution of 1905 was the Revolution in the Kingdom of Poland (1905–1907). The return to Poland's independence was a result of the First World War on the Polish lands (1914–1918), the overthrow of the Tsarist regime, and the defeat of the Central Powers in 1918.
=== The Deep Hot Biosphere === At the beginning of his 1992 paper The Deep Hot Biosphere, Thomas Gold referred to ocean vents in support of his theory that the lower levels of the earth are rich in living biological material that finds its way to the surface. He further expanded his ideas in the book The Deep Hot Biosphere. An article on abiogenic hydrocarbon production in the February 2008 issue of Science journal used data from experiments at the Lost City hydrothermal field to report how the abiotic synthesis of low molecular mass hydrocarbons from mantle derived carbon dioxide may occur in the presence of ultramafic rocks, water, and moderate amounts of heat.
Sources: en.wikipedia.org
=== Professional === The National Hockey League's Carolina Hurricanes franchise moved to Raleigh in 1997 from Hartford, Connecticut (where it was known as the Hartford Whalers). The team played its first two seasons more than 60 miles away at Greensboro Coliseum while its home arena, Raleigh Entertainment and Sports Arena (later RBC Center and now Lenovo Center), was under construction. The Hurricanes are the only major league (NFL, NHL, NBA, MLB) professional sports team in North Carolina to have won a championship, winning the Stanley Cup in 2006 and 2026. The city played host to the 2011 NHL All-Star Game.
==== MeSH D06.472.699 – peptide hormones ==== MeSH D06.472.699.009 – activins MeSH D06.472.699.009.500 – inhibin-beta subunits MeSH D06.472.699.054 – adiponectin MeSH D06.472.699.100 – bombesin MeSH D06.472.699.150 – calcitonin MeSH D06.472.699.200 – corticotropin-releasing hormone MeSH D06.472.699.275 – gastric inhibitory polypeptide MeSH D06.472.699.280 – gastrins MeSH D06.472.699.318 – glucagon precursors MeSH D06.472.699.318.249 – enteroglucagons MeSH D06.472.699.318.249.500 – glucagon-like peptide 1 MeSH D06.472.699.318.500 – glucagon MeSH D06.472.699.337 – inhibins MeSH D06.472.699.337.500 – inhibin-beta subunits MeSH D06.472.699.350 – insulin MeSH D06.472.699.350.408 – insulin, isophane MeSH D06.472.699.350.532 – insulin, long-acting MeSH D06.472.699.350.788 – proinsulin MeSH D06.472.699.350.788.250 – c-peptide MeSH D06.472.699.400 – leptin MeSH D06.472.699.500 – motilin MeSH D06.472.699.560 – msh release-inhibiting hormone MeSH D06.472.699.580 – msh-releasing hormone MeSH D06.472.699.584 – natriuretic peptides MeSH D06.472.699.584.500 – atrial natriuretic factor MeSH D06.472.699.584.625 – natriuretic peptide, brain MeSH D06.472.699.584.750 – natriuretic peptide, c-type MeSH D06.472.699.587 – pancreatic polypeptide MeSH D06.472.699.590 – parathyroid hormone MeSH D06.472.699.590.850 – teriparatide MeSH D06.472.699.591 – parathyroid hormone-related protein MeSH D06.472.699.592 – peptide phi MeSH D06.472.699.595 – peptide yy MeSH D06.472.699.600 – pituitary hormone release inhibiting hormones MeSH D06.472.699.620 – pituitary hormone-releasing hormones MeSH D06.472.699.631 – pituitary hormones MeSH D06.472.699.631.525 – pituitary hormones, anterior MeSH D06.472.699.631.525.343 – gonadotropins, pituitary MeSH D06.472.699.631.525.343.288 – follicle stimulating hormone MeSH D06.472.699.631.525.343.288.500 – follicle stimulating hormone, beta subunit MeSH D06.472.699.631.525.343.288.625 – follicle stimulating hormone, human MeSH D06.472.699.631.525.343.288.750 – glycoprotein hormones, alpha subunit MeSH D06.472.699.631.525.343.463 – luteinizing hormone MeSH D06.472.699.631.525.343.463.249 – glycoprotein hormones, alpha subunit MeSH D06.472.699.631.525.343.463.500 – luteinizing hormone, beta subunit MeSH D06.472.699.631.525.343.583 – menotropins MeSH D06.472.699.631.525.343.583.500 – urofollitropin MeSH D06.472.699.631.525.425 – growth hormone MeSH D06.472.699.631.525.425.875 – human growth hormone MeSH D06.472.699.631.525.525 – prolactin MeSH D06.472.699.631.525.690 – pro-opiomelanocortin MeSH D06.472.699.631.525.690.130 – corticotropin MeSH D06.472.699.631.525.690.130.050 – alpha-msh MeSH D06.472.699.631.525.690.130.200 – cosyntropin MeSH D06.472.699.631.525.690.480 – lipotropin MeSH D06.472.699.631.525.690.583 – melanocyte-stimulating hormones MeSH D06.472.699.631.525.690.583.050 – alpha-msh MeSH D06.472.699.631.525.690.583.075 – beta-msh MeSH D06.472.699.631.525.690.583.115 – gamma-msh MeSH D06.472.699.631.525.883 – thyrotropin MeSH D06.472.699.631.525.883.249 – glycoprotein hormones, alpha subunit MeSH D06.472.699.631.525.883.500 – thyrotropin, beta subunit MeSH D06.472.699.631.692 – pituitary hormones, posterior MeSH D06.472.699.631.692.433 – oxytocin MeSH D06.472.699.631.692.781 – vasopressins MeSH D06.472.699.631.692.781.100 – argipressin MeSH D06.472.699.631.692.781.100.250 – deamino arginine vasopressin MeSH D06.472.699.631.692.781.400 – lypressin MeSH D06.472.699.631.692.781.400.350 – felypressin MeSH D06.472.699.631.692.781.700 – ornipressin MeSH D06.472.699.631.692.881 – vasotocin MeSH D06.472.699.649 – placental hormones MeSH D06.472.699.649.367 – chorionic gonadotropin MeSH D06.472.699.649.367.125 – chorionic gonadotropin, beta subunit, human MeSH D06.472.699.649.367.562 – glycoprotein hormones, alpha subunit MeSH D06.472.699.649.451 – gonadotropins, equine MeSH D06.472.699.649.692 – placental lactogen MeSH D06.472.699.715 – relaxin MeSH D06.472.699.762 – resistin MeSH D06.472.699.810 – secretin MeSH D06.472.699.857 – somatostatin MeSH D06.472.699.905 – urotensins MeSH D06.472.699.952 – vasoactive intestinal peptide MeSH D06.472.699.976 – vasopressins MeSH D06.472.699.976.100 – argipressin MeSH D06.472.699.976.100.250 – deamino arginine vasopressin MeSH D06.472.699.976.400 – lypressin MeSH D06.472.699.976.400.350 – felypressin MeSH D06.472.699.976.700 – ornipressin
In the fields of medicine, biotechnology, and pharmacology, drug discovery is the process by which new candidate medications are discovered. Historically, drugs were discovered by identifying the active ingredient from traditional remedies or by serendipitous discovery, as with penicillin. More recently, chemical libraries of synthetic small molecules, natural products, or extracts were screened in intact cells or whole organisms to identify substances that had a desirable therapeutic effect in a process known as classical pharmacology. After sequencing of the human genome allowed rapid cloning and synthesis of large quantities of purified proteins, it has become common practice to use high-throughput screening of large compound libraries against isolated biological targets which are hypothesized to be disease-modifying in a process known as reverse pharmacology. Hits from these screens are then tested in cells and then in animals for efficacy. Modern drug discovery involves the identification of screening hits, medicinal chemistry, and optimization of those hits to increase the affinity, selectivity (to reduce the potential of side effects), efficacy and potency, metabolic stability (to increase the half-life), and oral bioavailability. Once a compound that fulfills all of these requirements has been identified, the process of drug development can continue. If successful, clinical trials are developed.
== History == Vancomycin was first isolated in 1953 by a research team led by chemist Edmund Kornfeld at Eli Lilly, from a soil sample provided by missionary William M. Bouw. The sample had been collected in 1952 within a forest on the island of Borneo, after Bouw took over collection duties from the Reverend William W. Conley, who had been a regular contributor to Lilly's global soil screening program since 1948. This program used a network of Christian and Missionary Alliance members to obtain specimens from remote locations to identify novel microorganisms. The organism within the soil that produced the antibiotic was a previously unknown streptomycete originally named Streptomyces orientalis (later reclassified as Amycolatopsis orientalis). Initially designated as "compound 05865", the substance was identified as a distinct antibiotic on June 18, 1953, when researcher Marvin Hoehn used paper chromatography to establish its unique "fingerprint." Unlike many contemporaneous samples that resulted in the rediscovery of known agents like chloromycetin, 05865 exhibited a novel chromatographic pattern and was found to be water-soluble. One of the most difficult tasks Kornfeld's team faced was purification. The early purification method employed during that time utilized picric acid (a potentially explosive chemical); because of this, an alternate process was developed. However, this new method yielded material with a purity of only 82% and, when solubilized, produced a brown liquid termed "Mississippi mud".
Sources: en.wikipedia.org
Solid NMN is generally stored in a sealed container at -20 °C or below, protected from light and moisture. Some suppliers recommend a desiccant and inert gas. Aqueous solutions are less stable and are often prepared fresh.
Liquid chromatography-mass spectrometry and nuclear magnetic resonance spectroscopy are common identity tests. HPLC with ultraviolet detection can assess purity by peak area. Results are usually compared with a certified reference standard.
Degradation can reduce the amount of intact NMN and create related impurities. Storage conditions and handling therefore affect measured purity and experimental reproducibility. Stability data also inform labeling and shelf-life claims.
NMN stands for nicotinamide mononucleotide. It is a nucleotide intermediate in the cellular pathway that produces NAD+, a coenzyme involved in energy metabolism and signaling. NMN is not the same compound as NAD+.